Drug recall · November 3, 2021
Rizatriptan Benzoate Orally Disintegrating Tablets 10mg recall
Why: Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Rizatriptan Benzoate Orally Disintegrating Tablets 10mg, 18 Tablets (3 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA, NDC 33342-094-41
- Lots / codes
Lot #: BRM2111A, BRM2112A, BRM2113A, BRM2114A, BRM2115A, BRM2116A, exp. date 04/2025
- Quantity
- 643,800 Blister Packs /888,336 Tablets
- Company
- Macleods Pharma USA, Inc, Princeton, NJ
- Distribution
- Nationwide within the United States
- Initiated
- October 18, 2021 · Voluntary: Firm initiated
- Classified
- October 28, 2021
- Reported
- November 3, 2021
- Ended
- April 24, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rizatriptan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.